|1.||Wright, Colin W: 8 articles (05/2013 - 04/2003)|
|2.||Olajide, Olumayokun A: 3 articles (05/2013 - 10/2009)|
|3.||Seville, Scott: 3 articles (07/2012 - 10/2007)|
|4.||Bhatia, Harsharan S: 2 articles (05/2013 - 01/2013)|
|5.||de Oliveira, Antonio C P: 2 articles (05/2013 - 01/2013)|
|6.||Fiebich, Bernd L: 2 articles (05/2013 - 01/2013)|
|7.||Paulo, Alexandra: 2 articles (02/2011 - 12/2010)|
|8.||Moreira, Rui: 2 articles (02/2011 - 12/2010)|
|9.||Lavrado, João: 2 articles (02/2011 - 12/2010)|
|10.||Pieters, L: 2 articles (12/2000 - 06/2000)|
02/10/2011 - "Overall, these novel cryptolepine analogues with substantially improved antiplasmodial activity and selectivity index provide a promising starting point for development of potent and highly selective agents against drug-resistant malaria parasites."
09/01/2013 - "Pharmacokinetics and in vivo chemosuppressive activity studies on cryptolepine hydrochloride and cryptolepine hydrochloride-loaded gelatine nanoformulation designed for parenteral administration for the treatment of malaria."
09/01/2013 - "The main objective of this investigation was to establish the pharmacokinetics profile and in vivo chemosuppressive activities of cryptolepine hydrochloride-loaded gelatine nanoparticles (CHN) designed for parenteral administration for the treatment of malaria in comparison to the drug free in solution (CHS). "
06/01/2012 - "Design and in vitro haemolytic evaluation of cryptolepine hydrochloride-loaded gelatine nanoparticles as a novel approach for the treatment of malaria."
07/01/2012 - "Cryptolepine (5-methyl-10H-indolo [3, 2-b] quinoline), an indoloquinoline alkaloid (1) isolated from a medicinal plant traditionally used in Western Africa for treatment of malaria, has been shown to possess broad spectrum biological activity in addition to its antiplasmodial effect. "
09/01/2013 - "Recent evidence suggests that the aqueous extract from the roots and the major alkaloid from the plant, cryptolepine, have prospects as cancer chemotherapeutic agents on account of their potent cytotoxicity to mammalian cells. "
10/01/2009 - "In conclusion, cryptolepine shows interesting in vitro cytotoxic properties and its further evaluation as an anti-cancer drug seems warranted."
12/01/2010 - "Three C-11 diamino cryptolepine derivatives, with significant chemical differences between the side chains, low cytotoxicity to mammalian non-tumor cells (Vero cells) and drug-like properties, were selected for anticancer drug screening in the NCI Developmental Therapeutics Program. "
04/14/1998 - "Altogether, the results provide direct evidence that DNA is the primary target of cryptolepine and suggest that this alkaloid is a valid candidate for the development of tumor active compounds."
10/01/2007 - "Molecular modelling studies suggest that cryptolepine is able to fit into the active site of NQO2 and thus raising the possibility that nitro-analogues of 1 could act as bioreductive prodrugs and be selectively reduced by NQO1 and NQO2 to more toxic species in cancer cells in which these enzymes are over-expressed. "
05/01/2013 - "In the present study we evaluated an extract of C. sanguinolenta (CSE) and cryptolepine (CAS) on neuroinflammation induced with IL-1β in SK-N-SH neuroblastoma cells. "
05/01/2013 - "Anti-neuroinflammatory properties of synthetic cryptolepine in human neuroblastoma cells: possible involvement of NF-κB and p38 MAPK inhibition."
|4.||Type 2 Diabetes Mellitus (MODY)
12/01/2000 - "With HL-60 human leukemia cells, the treatment with cryptolepine leads to the appearance of a hypo-diploid DNA content peak (sub-G1) characteristic of the apoptotic cell population. "
12/01/2000 - "Cryptolepine, and to a lesser extent neocryptolepine, provoke a massive accumulation of P388 murine leukemia cells in the G2/M phase. "
06/15/1999 - "The cellular consequences of the inhibition of topoisomerase II by cryptolepine were investigated using the HL60 leukemia cell line. "
11/01/1999 - "Biochemical experiments indicated that, in contrast to cryptolepine and matadine, usambarensine does not interfere with the catalytic activity of topoisomerase II. Human HL60 leukemia cells were used to assess the cytotoxicity of the alkaloid and its effect on the cell cycle. "
|3.||NRH - quinone oxidoreductase2
|4.||DNA (Deoxyribonucleic Acid)
|5.||Type II DNA Topoisomerases (Topoisomerase II)
|8.||Interleukin-1beta (Interleukin 1 beta)
|9.||p38 Mitogen-Activated Protein Kinases
|10.||Interleukin-6 (Interleukin 6)